Eckert & Ziegler stock at EUR 14.02, up 1.37% pre-market
Published on 11/10/2026 at 08:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points before the open
- Eckert & Ziegler is scheduled to report third-quarter results on November 12.
- The group develops isotope technology for cancer treatment, nuclear medicine and industrial radiometry.
- Investors are watching whether the upcoming report confirms an expected recovery in operating performance.
Eckert & Ziegler stock traded at 14.02 euros on Lang & Schwarz at 08:42 CET on Tuesday, November 10, 2026, 1.37 percent above the Xetra close of Monday, November 9.
Results due later this week
The next potential catalyst is the company's third-quarter report, scheduled for November 12. Global Banking & Finance Review lists the date and a revenue estimate of EUR 78.8 million. The report will give investors a fresh indication of demand, margins and the pace of the expected operating recovery.
Eckert & Ziegler develops isotope technology for medical, scientific and measurement applications. Its business is organized into the Medical and Isotope Products segments, with applications spanning cancer treatment, nuclear medicine and industrial radiometry. The company reported 2025 revenue of EUR 312.0 million and adjusted EBIT of EUR 77.7 million, according to its investor relations overview.
What investors will watch
- Third-quarter revenue and adjusted operating profit.
- Progress in radiopharmaceutical products and Actinium-225 supply.
- Any update on full-year expectations ahead of the year-end reporting cycle.
German equities provide the broader market context for the session; see the latest DAX market reports.
